ASMB · Assembly Biosciences, Inc.
$22.54
-0.44 (-1.91%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$479.90M
Shares
20.36M
Volume · Oct 2
368.31K
Avg daily vol (3M)
273.6K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.54
Open$23.30
Day$22.01–23.48
52W close$22.26–38.50
Avg vol 30d360K
Short int2.1M · 10.3% float · 6.3d
Short vol65%
Last earningsApr 17, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$74.84M
Trailing 12 months
Net income (TTM)
−$42,000
Trailing 12 months
Revenue growth YoY
+38.9%
Year over year
Operating margin
-11.8%
Trailing 12 months
P / E (TTM)
18.6
Trailing earnings · reciprocal yield 5.4%
FCF yield
-8.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+146.3%
Year over year · more shares
Price change (1Y)
-4.9%
Trailing year
Short interest
10.3%
Latest settlement · 6.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−22%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−38%
trailing
6-month return
−23%
trailing
YTD return
−34%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +33 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.29% of float · ▼ -1.2% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+154%
Y/Y
EPS growth
+92%
Y/Y
Free cash flow
$-41.2M
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $29 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+24% holders QoQ · +33 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.29% of float · ▼ -1.2% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22
Now $23 · 2%
Range high $39
vs 200-day avg -21%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASMB
this stock
Assembly Biosciences, Inc.
|
$479.90M | -33.7% | +153.5% | — | 10.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASMB | -4.8% | -37.6% | -22.9% | -4.0% | -33.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.6% | -37.2% | -35.1% | -5.0% | -46.6% |